Close Menu

NEW YORK (GenomeWeb) – Interpace Diagnostics said today that its molecular thyroid tests have received coverage for 3.8 million patients living in the Northeastern US from Horizon Blue Cross Blue Shield of New Jersey (Horizon BCBSNJ).

The payor has agreed to cover Interpace's ThyGenX and ThyraMir tests, effective Jan. 9, 2018, for thyroid nodules deemed indeterminate by standard cytopathological analysis, Interpace said. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jan
28
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Feb
05
Sponsored by
LGC

This webinar will provide a behind-the-scenes look at the collaborative development of a novel multiplex assay to speed detection of mosquito-borne illness in the clinical setting.